Mutational analyses of resistant disease or relapse/progression specimens
Outcome . | Patients, N = 25 . | Patients with mutation data, N = 22 . | Specimen collection times . |
---|---|---|---|
Imatinib 400 mg/d | |||
Stable disease | 6 | 1Mut: M244V | 31 days before removal from protocol treatment |
3 WT | 22 days before and 103 days after removal from protocol treatment; day 371 of protocol treatment | ||
Relapse from CHR | 8 | 1 Mut: E453K | 63 days before relapse |
7 WT | 6, 7, 14, 24, 78, and 672 days before; 658 days after relapse | ||
Progression | 1 | 1 WT | 4 days before removal from protocol treatment due to progression (patient was not adequately assessed for response) |
Dasatinib 100 mg/d | |||
Stable disease | 5 | 4 WT | 111 days before removal from protocol treatment; days 96, 329 and 374 of protocol treatment |
Relapse from CHR | 4 | 1Mut: V299L | Day of relapse |
3 WT | 52, 264, and 364 days before relapse | ||
Cytogenetic relapse | 1 | 1 WT | Day of cytogenetic relapse |
Outcome . | Patients, N = 25 . | Patients with mutation data, N = 22 . | Specimen collection times . |
---|---|---|---|
Imatinib 400 mg/d | |||
Stable disease | 6 | 1Mut: M244V | 31 days before removal from protocol treatment |
3 WT | 22 days before and 103 days after removal from protocol treatment; day 371 of protocol treatment | ||
Relapse from CHR | 8 | 1 Mut: E453K | 63 days before relapse |
7 WT | 6, 7, 14, 24, 78, and 672 days before; 658 days after relapse | ||
Progression | 1 | 1 WT | 4 days before removal from protocol treatment due to progression (patient was not adequately assessed for response) |
Dasatinib 100 mg/d | |||
Stable disease | 5 | 4 WT | 111 days before removal from protocol treatment; days 96, 329 and 374 of protocol treatment |
Relapse from CHR | 4 | 1Mut: V299L | Day of relapse |
3 WT | 52, 264, and 364 days before relapse | ||
Cytogenetic relapse | 1 | 1 WT | Day of cytogenetic relapse |
CHR indicates complete hematologic response; Mut, mutation; and WT, wild type.